FDA Staff Cuts Jeopardize Drug Reviews and the Future of US Health Regulation

A Looming Crisis at the FDA: Introduction

An unprecedented internal shakeup at the U.S. Food and Drug Administration (FDA) is sending shockwaves through the medical and pharmaceutical industries. The user fee system—an essential funding mechanism that powers the review and approval of new drugs, medical devices, and diagnostics—is now hanging by a thread. With mass layoffs and restructuring underway at the Department of Health and Human Services (HHS), experts fear the agency could regress to a time when life-saving treatments were mired in years-long approval delays.

This crisis is unfolding under the leadership of Health Secretary Robert F. Kennedy Jr., who has voiced strong skepticism about the FDA’s financial ties to the pharmaceutical industry. His aggressive budget cuts have sparked widespread concern, particularly regarding the future of biosimilar drugs—cheaper alternatives to brand-name biologics—which now face the greatest risk of disruption.

What’s Happening at the FDA?

The FDA’s drug and device review system is largely funded by user fees paid by pharmaceutical and medical device companies.
These fees cover up to 83% of the payroll for the Center for Drug Evaluation and Research (CDER), the FDA’s core drug review body.
Recent job cuts and contractor terminations are threatening the user fee system’s functionality.
By law, these fees can only be used if baseline government funding is maintained—which is now in doubt due to Kennedy’s cost-cutting efforts.
Dozens of staff involved in product reviews have already been laid off, compromising timelines for critical drug evaluations.
Analysts responsible for negotiating annual user fee revenue have also been removed, threatening the system’s long-term viability.
The biosimilar program, though currently meeting its spending trigger, has narrowly missed the mark in previous years and is now at high risk.
If spending benchmarks aren’t met, the FDA may be legally barred from using industry funds, effectively shutting down major review programs.
FDA officials warn that this could delay drug approvals, disrupt market competition, and even drive companies to seek regulatory approval abroad.
HHS claims these cuts are intended to “streamline operations” and “improve efficiency,” though many insiders dispute that narrative.

What Undercode Say:

This crisis marks a dangerous inflection point for the FDA, one that underscores the tension between regulatory integrity and operational dependence on industry funding. The user fee model, while controversial, has historically enabled the agency to process approvals in a timely, consistent manner. Removing or crippling this system threatens not only the FDA’s functionality but its very reputation as the global gold standard for drug safety and efficacy.

At the heart of the debate is the question: Can the FDA remain independent and effective while relying so heavily on industry money? Robert F. Kennedy Jr. has positioned himself as a watchdog against regulatory capture, raising concerns about the closeness between the agency and the industries it oversees. However, his sweeping cuts could cause more harm than good.

Consider the biosimilar drug review program, which plays a pivotal role in fostering affordable drug access. By destabilizing its funding, Kennedy’s actions may inadvertently increase healthcare costs by delaying competition. While cost-cutting might appeal in the short term, it undermines the infrastructure needed for long-term pharmaceutical innovation.

Equally concerning is the loss of institutional knowledge. Many of the dismissed employees were seasoned analysts and review specialists who helped maintain the delicate balance of scientific scrutiny and regulatory speed. Without them, not only will reviews slow down, but the quality of oversight may also degrade—something the American public can ill afford.

The bigger picture reveals a regulatory ecosystem in disarray. Layoffs of veterinarians, researchers, neuroscientists, and administrative staff point to a dismantling of federal health capabilities that extend well beyond drug approvals. Disease tracking, public health assistance, and medical research efforts—once the pride of U.S. federal institutions—now hang in the balance.

Even as HHS spokespersons promise to “mitigate risks,” internal chaos, demoralization, and staff shortages suggest these promises may be hollow. If Congress and HHS do not act swiftly to restore stability and staffing, the fallout could spread well beyond the FDA.

Meanwhile, drug companies are bracing for missed review deadlines, higher costs, and uncertainty over future approvals. If this instability persists, the U.S. could lose its edge in global pharmaceutical innovation, as companies begin to look to Europe or Asia for faster, more reliable regulatory paths.

Ultimately, this isn’t just an FDA issue—it’s a national health security issue. Undercutting the agency’s ability to function could delay treatments, hinder pandemic readiness, and leave millions without timely access to critical therapies. The integrity and efficiency of our health oversight institutions must not be sacrificed in the name of fiscal austerity.

Fact Checker Results:

User fees currently fund nearly 50% of the FDA’s overall budget and up to 83% of its drug evaluation center’s payroll.
Layoffs have directly impacted staff responsible for reviewing and negotiating these user fees.
Legal frameworks prevent the FDA from using collected industry funds if baseline government funding thresholds aren’t met.